These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Rapid switching between transdermal fentanyl and methadone in cancer patients. Mercadante S; Ferrera P; Villari P; Casuccio A J Clin Oncol; 2005 Aug; 23(22):5229-34. PubMed ID: 16051965 [TBL] [Abstract][Full Text] [Related]
4. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. Mercadante S; Ferrera P; Villari P; Casuccio A; Intravaia G; Mangione S J Pain Symptom Manage; 2009 Apr; 37(4):632-41. PubMed ID: 19345298 [TBL] [Abstract][Full Text] [Related]
5. Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors. Benítez-Rosario MA; Salinas-Martín A; Aguirre-Jaime A; Pérez-Méndez L; Feria M J Pain Symptom Manage; 2009 Jun; 37(6):1061-8. PubMed ID: 19171458 [TBL] [Abstract][Full Text] [Related]
6. Opioid plasma concentrations during a switch from transdermal fentanyl to methadone. Mercadante S; Villari P; Ferrera P; Casuccio A; Gambaro V J Palliat Med; 2007 Apr; 10(2):338-44. PubMed ID: 17472504 [TBL] [Abstract][Full Text] [Related]
7. From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial. Mystakidou K; Befon S; Kouskouni E; Gerolymatos K; Georgaki S; Tsilika E; Vlahos L Anticancer Res; 2001; 21(3C):2225-30. PubMed ID: 11501851 [TBL] [Abstract][Full Text] [Related]
8. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626 [TBL] [Abstract][Full Text] [Related]
9. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Sittl R; Likar R; Nautrup BP Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486 [TBL] [Abstract][Full Text] [Related]
10. Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine. Mercadante S; Porzio G; Fulfaro F; Aielli F; Verna L; Ficorella C; Casuccio A; Riina S; Intravaia G; Mangione S J Pain Symptom Manage; 2007 Nov; 34(5):532-8. PubMed ID: 17629666 [TBL] [Abstract][Full Text] [Related]
11. Early conversion from oral morphine to transdermal fentanyl in patients with cancer pain. Tani M; Fuku A; Terashita S; Kashiwagi H; Yukawa H; Yamaue H Hepatogastroenterology; 2008; 55(86-87):1545-8. PubMed ID: 19102339 [TBL] [Abstract][Full Text] [Related]
12. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain. Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811 [TBL] [Abstract][Full Text] [Related]
13. Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Lawlor PG; Turner KS; Hanson J; Bruera ED Cancer; 1998 Mar; 82(6):1167-73. PubMed ID: 9506365 [TBL] [Abstract][Full Text] [Related]
14. [Usefulness of fentanyl patch (Durotep) in cancer patients when rotated from morphine preparations]. Akiyama Y; Iseki M; Izawa R; Ishii K; Miyazaki T; Yamaguchi S; Tani Y Masui; 2007 Mar; 56(3):317-23. PubMed ID: 17366919 [TBL] [Abstract][Full Text] [Related]
15. A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids. Enting RH; Oldenmenger WH; van der Rijt CC; Wilms EB; Elfrink EJ; Elswijk I; Sillevis Smitt PA Cancer; 2002 Jun; 94(11):3049-56. PubMed ID: 12115396 [TBL] [Abstract][Full Text] [Related]
16. [Home palliative care--2 case reports: a long-term cancer pain management with transdermal fentanyl]. Fujimoto M; Sakuyama T; Mizutani Y; Kuroda T; Yanaga K Gan To Kagaku Ryoho; 2004 Dec; 31 Suppl 2():190-3. PubMed ID: 15645768 [TBL] [Abstract][Full Text] [Related]
17. Rotation to methadone after opioid dose escalation: How should individualization of dosing occur? Zimmermann C; Seccareccia D; Booth CM; Cottrell W J Pain Palliat Care Pharmacother; 2005; 19(2):25-31. PubMed ID: 16061458 [TBL] [Abstract][Full Text] [Related]
18. Intravenous methadone in the management of chronic cancer pain: safe and effective starting doses when substituting methadone for fentanyl. Santiago-Palma J; Khojainova N; Kornick C; Fischberg DJ; Primavera LH; Payne R; Manfredi P Cancer; 2001 Oct; 92(7):1919-25. PubMed ID: 11745266 [TBL] [Abstract][Full Text] [Related]
19. Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain. Tawfik MO; Bryuzgin V; Kourteva G; Curr Med Res Opin; 2004 Mar; 20(3):259-67. PubMed ID: 15025835 [TBL] [Abstract][Full Text] [Related]
20. A safe and effective method for converting patients from transdermal to intravenous fentanyl for the treatment of acute cancer-related pain. Kornick CA; Santiago-Palma J; Schulman G; O'Brien PC; Weigand S; Payne R; Manfredi PL Cancer; 2003 Jun; 97(12):3121-4. PubMed ID: 12784350 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]